Patents Issued in July 13, 2017
  • Publication number: 20170196909
    Abstract: An antiinfective-free formulation for prophylactic treatment of mastitis in dry cows comprises a seal formulation having approximately 65% by weight of bismuth sub-nitrate in a gel based on aluminium stearate. The seal formulation is prepared by adding the bismuth sub-nitrate to the gel base in at least two separate stages.
    Type: Application
    Filed: September 19, 2016
    Publication date: July 13, 2017
    Inventors: Vincent McNally, James Patrick Morgan
  • Publication number: 20170196910
    Abstract: A method of preparing and using gamma delta T cells in the allogeneic or autologous treatment of subjects suffering from virus infection, fungal infection, protozoal infection and cancer.
    Type: Application
    Filed: July 8, 2015
    Publication date: July 13, 2017
    Applicants: TC Biopharm LTD, TC Biopharm LTD
    Inventors: Michael LEEK, Adele HANNIGAN
  • Publication number: 20170196911
    Abstract: Provided herein are methods of enhancing engraftment of hematopoietic stem cells (HSC) in recipient subjects by reducing expression (or activity) of CXC chemokine receptor 4 (CXCR4). Such methods can be used in gene therapy protocols and in HSC transplantation, for example allowing this to occur without radiation or chemotherapy conditioning as is typically done in non-myeloablative HSC transplant. In some examples, gene editing methods are used to delete one copy of the CXCR4 gene before HSC or bone marrow transplantation, enhancing the efficiency and durability of donor cell repopulation.
    Type: Application
    Filed: July 17, 2015
    Publication date: July 13, 2017
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Jiliang Gao, Philip M. Murphy, David H. McDermott, Marie Siwicki, Harry L. Malech, Joy Liu, Paejonette Jacobs
  • Publication number: 20170196912
    Abstract: The present invention provides novel stem cell compositions having significant therapeutic and practical advantages, as well as methods of preparing and using such compositions for the treatment and prevention of injury and disease in patients. The invention may be applied to stem cell populations isolated from a wide variety of animals, including humans, and tissues. In particular applications, the invention is used to prepare a stem cell composition from a collagen-based tissue, such as adipose tissue, isolated from a patient, and the stem cell composition is subsequently provided to a site of actual or potential injury in the patient. The invention further includes related kits comprising the stem cell compositions, which are remarkably stable and retain viability and efficacy during storage and shipment.
    Type: Application
    Filed: August 19, 2016
    Publication date: July 13, 2017
    Inventors: Robert J. Harman, JR., Theodore T. Sand
  • Publication number: 20170196913
    Abstract: Methods for increasing glucose induced insulin secretion in an insulin secreting cell by inducing senescence in the cell are provided. Further, methods for treating diabetes, by providing cells with increased glucose induced insulin secretion to a subject, as well as a population of modified insulin secreting cells are provided.
    Type: Application
    Filed: January 9, 2017
    Publication date: July 13, 2017
    Inventors: Ittai BEN-PORATH, Yuval DOR, Aharon HELMAN, Agnes KLOCHENDLER
  • Publication number: 20170196914
    Abstract: Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.
    Type: Application
    Filed: January 25, 2017
    Publication date: July 13, 2017
    Inventors: Gregory McKenzie, Mary-Jane Lombardo McKenzie, David N. Cook, Marin Vulic, Geoffrey von Maltzahn, Brian Goodman, John Grant Aunins, Matthew R. Henn, David Arthur Berry, Jonathan Winkler
  • Publication number: 20170196915
    Abstract: Dietary supplements comprising at least one probiotic and at least one of animal digest, dried brewers yeast, vitamin C; vitamin E, beta carotene, zinc proteinate, manganese proteinate, ferrous sulfate, copper proteinate, calcium iodate, and sodium selenite. The probiotics and other ingredients are present in the supplement in amounts sufficient to enhance the palatability of the probiotics and compositions containing the probiotics, enhance the immune system to augment the beneficial effects of the probiotics, or extend the life of the probiotics.
    Type: Application
    Filed: March 27, 2017
    Publication date: July 13, 2017
    Inventors: Gail Czarnecki-Maulden, Ivan Filipi, Christoph Cavadini
  • Publication number: 20170196916
    Abstract: The present invention is based upon the findings of two large clinical studies to determine the efficacy of daily consumption of the probiotic strain Bifidobacterium animalis subsp. lactis deposited as DSM 15954 for 4 weeks on abdominal pain in postmenopausal women. Bifidobacterium animalis subsp. lactis significantly reduced abdominal pain. Accordingly, the present invention relates to a probiotic product comprising Bifidobacterium animalis subsp. lactis for use in reducing abdominal pain in a postmenopausal woman. The invention further relates to a method for reducing abdominal pain in a postmenopausal woman, the method comprising administering a probiotic product comprising Bifidobacterium animalis subsp. lactis to the postmenopausal woman.
    Type: Application
    Filed: August 24, 2015
    Publication date: July 13, 2017
    Applicant: CHR. HANSEN A/S
    Inventors: Dorte ESKESEN, Lillian JESPERSEN, Cathrine Melsaether MORBERG, Birgit MICHELSEN
  • Publication number: 20170196917
    Abstract: An agent for the prevention and treatment of chlamydia infection containing Lactobacillus casei as an active ingredient which is an agent for the prevention and treatment of chlamydia infection that is highly safe and that can be administered over an extended period of time.
    Type: Application
    Filed: May 14, 2015
    Publication date: July 13, 2017
    Applicant: KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Takashi ASAHARA, Akira TAKAHASHI, Koji NOMOTO, Takashi KURAKAWA, Shoichi KADO, Norikatsu YUKI, Takuya TAKAHASHI
  • Publication number: 20170196918
    Abstract: The invention relates to a bacterial strain, Lactobacillus casei IPLA12038 with deposit number CECT 8590, and its use for the degradation of gluten, gliadin or derivative peptides. The strain has been isolated from an acidic dough used to make bread. Its advantages include the ability to use gliadin as nitrogen source, possess peptidase activities involved in the degradation of it and be able to completely degrade the immunotoxic (33) amino acid peptide involved in triggering of celiac disease in a short period of time. The fact of considering it a GRAS and QPS microorganism, isolated from a fermented food, sensitive to antimicrobial gastrointestinal agents and resistant to gastrointestinal conditions tested in vitro, guarantees its use as a probiotic or nutraceutical supplement.
    Type: Application
    Filed: May 22, 2015
    Publication date: July 13, 2017
    Inventors: Patricia Alvarez Sieiro, Maria Cruz Martin Martin, Begona Redruello Trelles, Victor Ladero Losada, Maria Fernandez Garcia, Miguel Angel Alvarez Gonzalez
  • Publication number: 20170196919
    Abstract: The invention relates to probiotic bacteria and particularly, although not exclusively, to anti-bacterial compositions derived from probiotic bacteria. Disclosed are compositions comprising material secreted from probiotic bacteria, uses thereof, and methods using the compositions. Particularly contemplated are compositions comprising material secreted from Lactobacillus rhamnosus, and uses thereof.
    Type: Application
    Filed: May 26, 2015
    Publication date: July 13, 2017
    Inventors: Catherine O'NEILL, Andrew MCBAIN
  • Publication number: 20170196920
    Abstract: A composition for treating hyperadrenocorticism includes a therapeutically effective amount of a pharmaceutical dosage form including melatonin, lignan, phosphatidylserine, and at least one probiotic organism-containing material. The composition may be used to treat canine Cushing's disease, for example.
    Type: Application
    Filed: January 6, 2017
    Publication date: July 13, 2017
    Inventor: James Marshall, III
  • Publication number: 20170196921
    Abstract: The disclosure relates to isolated microorganisms—including novel strains of the microorganisms—microbial consortia, and compositions comprising the same. Furthermore, the disclosure teaches methods of utilizing the described microorganisms, microbial consortia, and compositions comprising the same, in methods for modulating the production and yield of milk and milk components in ruminants. In particular aspects, the disclosure provides methods of increasing desirable components of milk in ruminants. Furthermore, the disclosure provides for methods of modulating the rumen microbiome.
    Type: Application
    Filed: January 6, 2017
    Publication date: July 13, 2017
    Inventors: Mallory Embree, Luke Picking, Grant Gogul, Janna Tarasova
  • Publication number: 20170196922
    Abstract: The disclosure relates to isolated microorganisms—including novel strains of the microorganisms—microbial consortia, and compositions comprising the same. Furthermore, the disclosure teaches methods of utilizing the described microorganisms, microbial consortia, and compositions comprising the same, in methods for modulating the production and yield of milk and milk components in ruminants. In particular aspects, the disclosure provides methods of increasing desirable components of milk in ruminants. Furthermore, the disclosure provides for methods of modulating the rumen microbiome.
    Type: Application
    Filed: January 6, 2017
    Publication date: July 13, 2017
    Inventors: Mallory Embree, Luke Picking, Grant Gogul, Janna Tarasova
  • Publication number: 20170196923
    Abstract: The present invention provides a commercial process for preparing the ‘Cannabis-Hemp Paste’ into a food grade nutritional supplement. The process produces both a fully cooked, and raw food product combined, that can be inserted into an edible consumption vessel of any type, or placed into the mouth, and/or stomach, for ingestion purposes. The commercial process entails the combining of various terpenes, flavonoids, decarboxylated cannabinoids (and various raw cannabinoids) that are found in the Cannabis-Hemp Plant; with various fats and thickeners for the purposes of creating a ‘paste’ that can be ingested and metabolized as a food grade dietary supplement, and/or as a direct food product. To accomplish this process, a quantity of the Cannabis-Hemp Plant must be raw and pressed, and a quantity of the Cannabis-Hemp Plant must be heat-cooked and blended with fresh fats; the heat-cooked Cannabis-Hemp plant must then be repeatedly heat-cooked in a steam kettle and pressed to extract different amalgams.
    Type: Application
    Filed: January 12, 2016
    Publication date: July 13, 2017
    Inventor: David Harold Moore
  • Publication number: 20170196924
    Abstract: The present invention is a composition comprising: (a) protein selected from the group consisting of soy protein and pea protein; (b) sunflower seed protein; (c) turmeric; and (d) bitter melon. The composition is useful as a dietary supplement, a food, a complementary medicine or a therapeutic agent. Furthermore, the composition may be prepared in any form including, for example, powder, emulsion, liquid, capsule, pill and food items such as nutrition bars.
    Type: Application
    Filed: December 15, 2016
    Publication date: July 13, 2017
    Inventor: Timothy J. O'Brien
  • Publication number: 20170196925
    Abstract: An aqueous formulation comprising between 0.1% and 50% by weight of lipophilic composition, said formulation further comprising between 0.1% and 10% by weight of homogenising component comprising at least microcrystalline cellulose; between 0.01% and 2% by weight of clay; and the remainder in water.
    Type: Application
    Filed: January 9, 2017
    Publication date: July 13, 2017
    Inventors: Nicolas Vidal, Jean-Francois Lesgards
  • Publication number: 20170196926
    Abstract: Use of Cistanche tubulosa extract, isoacteoside and/or a pharmaceutical acceptable salt of isoacteoside in the manufacture of a medicament or a food product for protecting muscles, wherein the medicament is particularly used for protecting muscle cells against injury to regulate, treat and/or delay muscle loss, and especially for the muscle loss caused by aging, diseases, and/or cochexia. The food product is a health food, a nutritional supplement food, or a special nutrition food.
    Type: Application
    Filed: January 11, 2017
    Publication date: July 13, 2017
    Inventors: Chao-Jih WANG, Ai-Ling YEH
  • Publication number: 20170196927
    Abstract: The present invention relates to a composition comprising green tea extract, collagen and chondroitin. Such a composition can be used for use in treating or preventing arthritis, for increasing life expectancy in an animal, for preventing signs of aging, for use in preserving mobility or preventing decline in mobility in an animal and in a method for making such compositions. The composition can be also used in a method of treating arthritis, a method of increasing life expectancy, a method of preserving mobility or preventing decline in mobility or a method of delaying aging.
    Type: Application
    Filed: May 21, 2015
    Publication date: July 13, 2017
    Applicant: Mars, Incorporated
    Inventor: Samuel SERISIER
  • Publication number: 20170196928
    Abstract: A composition for the treatment of Demodex blepharitis containing tea tree oil and/or Neem oil and coconut oil in glycerol or in water or in a mixture of glycerol and water. The composition may further contain aloe barbadensis gel, sodium lauryl sulfate, cocoamidopropyl betaine, lauroyl glucoside, or DMDM hydantoin, or a combination thereof, in glycerol or in water or in a mixture of glycerol and water. The composition is used to treat Demodex blepharitis by applying the composition to the eyelid margin and eyelashes and scrubbing the eyelid margin, eyelashes, and eyelash roots with the composition using any suitable cloth, wipe, sponge, brush, or cotton tipped applicator.
    Type: Application
    Filed: May 26, 2015
    Publication date: July 13, 2017
    Inventors: Jeffery McAnnally, John O. Mason, III
  • Publication number: 20170196929
    Abstract: The present disclosure relates to a formulation for preventing and treating cancer which avoids the undesirable side effects observed when using the conventional therapies. The formulation in accordance with the present disclosure comprises a formulation having active constituents comprising a combination of extracts from Boswellia spp, Curcuma longa and Vitis vinifera.
    Type: Application
    Filed: January 6, 2015
    Publication date: July 13, 2017
    Inventors: Jatin THAKKAR, Gisli Örn LÁRUSSON
  • Publication number: 20170196930
    Abstract: The patent provides a process of preparing a pharmaceutical preparation of glatiramer acetate and mannitol in a suitable container comprising the steps of: (i) obtaining an aqueous pharmaceutical solution of glatiramer acetate and mannitol; (ii) filtering the aqueous pharmaceutical solution at a temperature of from above 0° C. up to 17.5° C. to produce a filtrate; and (iii) filling the suitable container with the filtrate obtained after performing step (ii), so as to thereby prepare the pharmaceutical preparation of glatiramer acetate and mannitol in the suitable container. This patent further provides an aqueous pharmaceutical solution comprising 40 mg/ml glatiramer acetate and 40 mg/ml mannitol, wherein the aqueous pharmaceutical solution a) has a viscosity in the range of 2.0-3.5 cPa; or b) has an osmolality in the range of 275-325 mosmol/Kg. This patent also provides a prefilled syringe, an automated injector and a method of treatment of a human patient.
    Type: Application
    Filed: March 28, 2017
    Publication date: July 13, 2017
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Rakefet Cohen, Sasson Habbah, Muhammad Safadi
  • Publication number: 20170196931
    Abstract: The present disclosure relates to the use of angiotensinogen, angiotensin I, angiotensin I, angiotensin III, and/or angiotensin IV in therapeutic methods for the treatment of hypotension, such as catecholamine-resistant hypotension.
    Type: Application
    Filed: January 6, 2017
    Publication date: July 13, 2017
    Inventor: Lakhmir Chawla
  • Publication number: 20170196932
    Abstract: The present invention relates to a pharmaceutical composition containing leuprolide acetate and having both immediate and sustained release properties and, more specifically, to a pharmaceutical composition in which, on the basis of the total weight of active ingredients, leuprolide as an immediate release preparation is contained in 0.001 wt % to 25 wt %; and leuprolide contained in microspheres of a sustained release preparation is contained in 75 wt % to 99.999 wt %. The pharmaceutical composition of the present invention is characterized by satisfying both a drug immediate release property so as to realize the prompt exposure to a sufficient amount of drug at the early stage for expression of medicinal effects and a drug sustained release property for four weeks or longer, and the pharmaceutical composition is effective in the prevention and treatment of sex hormone-dependent positive or malignant diseases.
    Type: Application
    Filed: January 27, 2017
    Publication date: July 13, 2017
    Inventors: Hong Kee Kim, Kyu Ho Lee, Seok Hyun Hong, Yong-kyu Kwak, Ho Chul Shin, Hun-Teak Kim
  • Publication number: 20170196933
    Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2?,6?-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2?,6?-Dmt-Lys-Phe-NH2.
    Type: Application
    Filed: May 27, 2015
    Publication date: July 13, 2017
    Inventor: D. Travis Wilson
  • Publication number: 20170196934
    Abstract: An oral composition comprising minicapsules wherein the minicapsules comprise one or more therapeutic prophylactic substances in a liquid, semi-liquid, or solid core. The minicapsules have release profiles to release the substance in an active form at one or more sites along the gastro-intestinal tract to maximise absorption and/or therapeutic efficiency.
    Type: Application
    Filed: January 19, 2017
    Publication date: July 13, 2017
    Applicant: Sigmoid Pharma Limited
    Inventor: Ivan Coulter
  • Publication number: 20170196935
    Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.
    Type: Application
    Filed: August 19, 2016
    Publication date: July 13, 2017
    Inventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
  • Publication number: 20170196936
    Abstract: The present invention relates to methods of treating or preventing a complement-mediated disease and/or disorder in a subject with a complement C5 polymorphism, including administering to a subject in need thereof a therapeutically or prophylactically effective amount of an agent that a) inhibits the classical complement pathway, the alternative complement pathway and the lectin complement pathway; and/or b) inhibits eicosanoid activity. The invention also relates to methods of identifying patient populations with C5 polymorphisms that are treatable with specific agents that a) inhibit the classical complement pathway, the alternative complement pathway and the lectin complement pathway; and/or b) inhibit eicosanoid activity.
    Type: Application
    Filed: June 8, 2015
    Publication date: July 13, 2017
    Applicant: Volution Immuno Pharmaceuticals SA
    Inventor: Wynne H. Weston-Davies
  • Publication number: 20170196937
    Abstract: The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and fosfomycin for the treatment, prevention or alleviation of an inflammatory bowel disease such as Crohn's disease, ulcerative colitis or necrotizing enterocolitis of newborn and premature infants by administration of the compositions into the intestinal lumen.
    Type: Application
    Filed: July 24, 2015
    Publication date: July 13, 2017
    Inventors: Lars Heslet, Lars Otto Uttenthal
  • Publication number: 20170196938
    Abstract: The present disclosure provides compositions and methods for efficient and effective protein delivery in vitro and in vivo. In some aspects, proteins are reversibly crosslinked to each other and/or modified with functional groups and protected from protease degradation by a polymer-based or silica-based nanoshell.
    Type: Application
    Filed: March 27, 2017
    Publication date: July 13, 2017
    Inventors: Li TANG, Darrell J. IRVINE
  • Publication number: 20170196939
    Abstract: A formulation of a diluted amino acid fragment is prepared by mixing an amino acid fragment and a diluting agent to form a mixture. The mixture is serially diluted to produce a diluted formulation. The amino acid fragment includes a peptide sequence that is the same as a portion of a longer peptide sequence found in a naturally occurring material. A homeopathic remedy can be prepared using the formulation.
    Type: Application
    Filed: March 27, 2017
    Publication date: July 13, 2017
    Applicant: Deseret Biologicals, Inc.
    Inventors: Jacob L. Carter, Edwin Douglas Lephart
  • Publication number: 20170196940
    Abstract: Provided are oxyntomodulin analogs. The peptide analogs have at least two cysteines. The two cysteines are separated by six amino acids such that they can be crosslinked using suitable crosslinking moieties. The crosslinked peptides have long half-lives and/or efficacy. For example, peptide analog compositions are used for inducing weight loss and/or reducing blood glucose levels.
    Type: Application
    Filed: March 7, 2017
    Publication date: July 13, 2017
    Inventors: Qing Lin, Avinash Muppidi, Weijun Shen, Huafei Zou, Peter Schultz, Yulin Tian
  • Publication number: 20170196941
    Abstract: A high-purity inhalable insulin material, used for preparing a pulmonary pharmaceutical product, includes insulin particles having a particle size at the micrometer level and having the following characteristics: (i) the purity of insulin is not less than 96% on the dried basis; (ii) the total amount of insulin-related impurities is not more than 2%; (iii) the total amount of solvent impurities, which is not a co-solvent formulation component for a pulmonary product, is not more than 0.03%; and (iv) the total amount of non-solvent impurities is not more than 0.3%. Up to 99% by volume of the insulin particles in the inhalable insulin have a particle size of less than 5 ?m, based on the total volume of the insulin particles. A high-efficiency method prepares high-purity inhalable insulin material. The yield rate for the high-efficiency method is 75 to 85% or more.
    Type: Application
    Filed: January 7, 2016
    Publication date: July 13, 2017
    Inventors: Jeffrey Ding, Aili Bo, Mary Ziping Luo, Jack Yongfeng Zhang
  • Publication number: 20170196942
    Abstract: A high-purity inhalable insulin material, used for preparing a pulmonary pharmaceutical product, includes insulin particles having a particle size at the micrometer level and having the following characteristics: (i) the purity of insulin is not less than 96% on the dried basis; (ii) the total amount of insulin-related impurities is not more than 2%; (iii) the total amount of solvent impurities, which is not a co-solvent formulation component for a pulmonary product, is not more than 0.03%; and (iv) the total amount of non-solvent impurities is not more than 0.3%. Up to 99% by volume of the insulin particles in the inhalable insulin have a particle size of less than 5 ?m, based on the total volume of the insulin particles. A high-efficiency method prepares high-purity inhalable insulin material. The yield rate for the high-efficiency method is 75 to 85% or more.
    Type: Application
    Filed: September 29, 2016
    Publication date: July 13, 2017
    Applicant: Amphastar Pharmaceuticals Inc.
    Inventors: Jeffrey Ding, Aili Bo, Mary Ziping Luo, Jack Yongfeng Zhang
  • Publication number: 20170196943
    Abstract: A composition for preventing or treating diabetes mellitus includes insulin and a GLP-1/glucagon dual agonist. The composition can inhibit the weight gain and reduce the danger of hypoglycemia due to the administration of insulin, lower the administration dose and greatly improve the compliance of drugs through a combined administration of a long-acting insulin conjugate and a long-acting GLP-1/glucagon dual agonist conjugate. In addition, the long-acting insulin conjugate and the long-acting GLP-1/glucagon dual agonist conjugate can improve the in vivo sustainability and stability because an insulin and a GLP-1/glucagon dual agonist are linked to the immunoglobulin Fc region via a non-peptidyl linker. A method for preventing or treat diabetes mellitus includes administration of the insulin and a GLP-1/glucagon dual agonist.
    Type: Application
    Filed: June 1, 2015
    Publication date: July 13, 2017
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Sung Youb JUNG, Sang Youn HWANG, Seung Su KIM, In Young CHOI, Se Chang KWON
  • Publication number: 20170196944
    Abstract: A method for reducing muscle atrophy in an individual undergoing orthopedic surgery, the method comprising administering to said individual a mixture of protein and non-protein nutrients for 4-7 days pre-surgery and for 10-21 days post-surgery. The protein dosage is 15-30 g, of which 17-25% is leucine, 23-35% is 1-glutamine, 10-15% is 1-arginine and 1-2% is cysteine. The protein nutrients are derived from a combination of commercially available proteins and the appropriate free amino acid. The non-protein nutrients are a mono or disaccharide in the amount of 15-30%, N-acetyl-cysteine in the amount of 1-15% and the antioxidant Vitamin C.
    Type: Application
    Filed: September 28, 2015
    Publication date: July 13, 2017
    Inventor: ROBERT PORTMAN
  • Publication number: 20170196945
    Abstract: Embodiments of the technology described herein are based upon the discoveries that neutrophil extracellular traps (NETs) provide a stimulus for thrombus formation and that NETs are present in stored blood products. Accordingly, some embodiments relate to methods of treating and preventing toxicity of NETs and thrombosis caused by NETs. Additional embodiments are directed towards methods of treating stored blood products to prevent transfusion-related injuries.
    Type: Application
    Filed: March 30, 2017
    Publication date: July 13, 2017
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Denisa D. Wagner, Tobias A. Fuchs, Simon De Meyer, Kimberly Martinod, Alexander Brill, Grace M. Thomas
  • Publication number: 20170196946
    Abstract: Botulinum toxin is combined with colloidal silver particles to provide improved compositions for use in medical and cosmetic treatments.
    Type: Application
    Filed: January 25, 2017
    Publication date: July 13, 2017
    Inventors: Keith William Moeller, Andrew J.M. Willoughby
  • Publication number: 20170196947
    Abstract: The disclosure relates to a peptide (SEQ ID NO: 5), the use of said peptide for the treatment of the symptoms associated with pain, the use of said peptide for the inhibition of the activity of influenza virus and a pharmaceutical composition containing the peptide.
    Type: Application
    Filed: March 20, 2017
    Publication date: July 13, 2017
    Inventor: Chenlung Lin
  • Publication number: 20170196948
    Abstract: The present invention pertains to a dendritic cell-based vaccine against rh-?-Syn, ?-synuclein specific peptide antibodies and related vaccines, and methods of treating, preventing, and/or vaccinating against Parkinson's Disease (PD), or symptoms thereof.
    Type: Application
    Filed: May 26, 2015
    Publication date: July 13, 2017
    Applicant: University of South Florida
    Inventors: Chuanhai Cao, Xiaoyang Lin
  • Publication number: 20170196949
    Abstract: The present invention relates to a method for prevention and/or treatment of an autoimmune disease, comprising administering a composition, said composition comprising at least one beta cell autoantigen, to a subject The subject may have a serum vitamin-D level above 50 nanomole/liter or the composition may be administered by intralymphatic injection or injection directly into a lymph node, or over a period of weeks, months, or years.
    Type: Application
    Filed: June 4, 2015
    Publication date: July 13, 2017
    Inventors: Anders ESSEN-MÖLLER, Johnny LUDVIGSSON
  • Publication number: 20170196950
    Abstract: The invention relates to a method for producing tolerogenic dendritic cells (tolDCs) with specific antigens, comprising the steps of: (a) culturing precursors of dendritic cells in an animal-serum-free medium, using cytokines, IL-4 and GM-CSF, in order to differentiate same in dendritic cells; (b) producing apoptotic cells; (c) culturing the dendritic cells obtained in step (b) in the presence of compounds having anti-inflammatory activity; (d) co-culturing the dendritic cells from step (d) with the apoptotic cells from step (c), such as to stimulate the endocytosis of the apoptotic cells by the dendritic cells; (e) and, by means of identification based on phenotypic evaluation, determining the production of tolerogenic dendritic cells (tolDCs) with specific antigens. The invention also relates to the tolDC cells produced with said method and to the use of said tolDCs with specific antigens in the production of a drug suitable for the treatment of systemic lupus erythematosus.
    Type: Application
    Filed: June 5, 2015
    Publication date: July 13, 2017
    Applicant: PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE
    Inventors: Carolina LLANOS MUNOZ, Alexis Mikes KALERGIS PARRA, Fabian Alejandro VEGA TAPIA, Andy lgor TORRES BAEZA
  • Publication number: 20170196951
    Abstract: Compositions of matter, of production, and treatment modalities are disclosed for the prevention and/or therapeutic reduction of tumors through induction of immunity against tumor associated fibroblasts and components of tumor microenvironment. In one embodiment of the invention, placentally derived fibroblast cells are cultured under conditions replicating tumor microenvironment. Expression of CD248 on said cultured fibroblasts is used as a marker of effective manipulation. Cells expressing CD248 are utilized a immunogens for stimulation of immunity towards cancer associated fibroblastic cells.
    Type: Application
    Filed: August 8, 2016
    Publication date: July 13, 2017
    Inventors: Samuel C. Wagner, Thomas E. Ichim, Amit N. Patel
  • Publication number: 20170196952
    Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding an ESR1 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the ESR1 polypeptide to treat a cancer or precancer are also provided.
    Type: Application
    Filed: July 7, 2015
    Publication date: July 13, 2017
    Applicant: Duke University
    Inventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
  • Publication number: 20170196953
    Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER2 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the HER2 polypeptide to treat a cancer or precancer are also provided. The vaccines may be administered with a cancer therapeutic or prevention agent or a checkpoint inhibitor immunomodulatory agent.
    Type: Application
    Filed: July 7, 2015
    Publication date: July 13, 2017
    Applicant: Duke University
    Inventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
  • Publication number: 20170196954
    Abstract: Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject a robust immune response. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of a humoral immune response and/or cellular immune response is desired and beneficial.
    Type: Application
    Filed: July 14, 2015
    Publication date: July 13, 2017
    Inventors: Richard KENNEY, Frank HSU, Jan Henrik TER MEULEN, Peter Lars Aksel BERGLUND
  • Publication number: 20170196955
    Abstract: The present invention relates to a method for preparing a dendritic cell, a dendritic cell prepared thereby and a use thereof, and more specifically, to a method for preparing a dendritic cell, including: treating a dendritic cell at a maturation stage rather than at an immature stage with an antigen bound to a peptide having a cell membrane permeability to prepare a dendritic cell with improved antigen-presenting ability, a dendritic cell prepared by the method, and an immunotherapeutic agent thereof, a use for anti-tumor vaccines, or a pharmaceutical composition for treating tumors, containing the same.
    Type: Application
    Filed: July 28, 2015
    Publication date: July 13, 2017
    Inventors: Yoon Lee, Young-Mok Kim, So-Yeon Kim, Seung-Soo Han, Yong-Soo Bae
  • Publication number: 20170196956
    Abstract: Isolated KIF20A-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce KIF20A-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.
    Type: Application
    Filed: December 20, 2016
    Publication date: July 13, 2017
    Inventors: Yasuharu Nishimura, Yusuke Tomita, Ryuji Osawa
  • Publication number: 20170196957
    Abstract: Disclosed herein are compositions and methods for treating or inhibiting prostate cancer. The compositions include a MHC molecule including covalently linked first and second domains, wherein the first domain is an MHC class II ?1 domain and the second domain is an MHC class II ?1 domain, wherein the amino terminus of the ?1 domain is covalently linked to the carboxy terminus of the ?1 domain, and a prostate specific antigen peptide covalently linked to the first domain. The methods include administering a disclosed MHC molecule to a subject with prostate cancer.
    Type: Application
    Filed: January 6, 2017
    Publication date: July 13, 2017
    Applicants: Oregon Health & Science University, The United States Government as Represented by the Department of Veterans Affairs, University of Maryland, Baltimore
    Inventors: Arthur A. Vandenbark, Roberto Meza-Romero, Richard Alexander, Elena Klyushnenkova
  • Publication number: 20170196958
    Abstract: The disclosure relates to a glycoconjugate vaccine conferring protection against Francisella tularensis infections and a method to manufacture a glycoconjugate antigen.
    Type: Application
    Filed: March 21, 2017
    Publication date: July 13, 2017
    Applicant: London School of Hygiene and Tropical Medicine
    Inventors: Brendan Wren, Jon Cuccui, Madeleine Moule